Acadia Pharmaceuticals (ACAD) PT Raised to $23 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
Go back to Acadia Pharmaceuticals (ACAD) PT Raised to $23 at Oppenheimer
December 7, 2021 8:17 AM EST
Shares of Acadia Pharma (NASDAQ: ACAD) are up nearly 20% in pre-open Tuesday after the company reported positive top-line results from the pivotal Phase 3 study related to Rett syndrome.
The consistent efficacy across primary and key secondary endpoints in the Lavender study demonstrates the potential of trofinetide to treat Rett syndrome, said Kathie Bishop,... More
December 7, 2021 6:39 AM EST
Goldman Sachs analyst Salveen Richter raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $28.00 (from $25.00) while maintaining a Neutral rating.
...
More
December 7, 2021 6:30 AM EST
Mizuho Securities analyst Vamil Divan raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $26.00 (from $24.00) while maintaining a Neutral rating.
The analyst commented, "Acadia has released top-line data for their pipeline asset trofinetide for the treatment of Rett syndrome. While... More
December 7, 2021 6:14 AM EST
On December 6th, after market closed, Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced positive top-line results from the pivotal, Phase 3 Lavender study evaluating the efficacy and safety of trofinetide in 187 girls and young women aged 5-20 years with Rett syndrome.Acadia Pharma (NASDAQ: ACAD)
The... More
